Rational Vaccines Inc
Rational Vaccines is an infectious disease company focused on developing vaccines and therapeutics to combat herpes simplex virus (HSV-1 and HSV-2) infections. They aim to revolutionize the treatment, prevention, and diagnosis of herpes and herpes-related diseases worldwide through proprietary technology and rationally engineered live attenuated viral vaccines. The company is also involved in COVID-19 testing and vaccine development, leveraging their expertise in viral immunotherapeutics.
Industries
Nr. of Employees
small (1-50)
Products
Therapeutic live-attenuated HSV-2 vaccine candidate (lead)
A replication-competent, rationally attenuated herpesvirus vaccine candidate designed to modulate immune control of recurrent HSV infection via targeted mutations that reduce immune evasion; progressed through preclinical development with reported early clinical safety follow-up.
Prophylactic live-attenuated HSV vaccine candidates (HSV-1 and HSV-2)
Preclinical-stage replication-competent vaccine candidates intended for prevention of HSV-1 and HSV-2 infection developed using rational attenuation principles.
Multi-antigen IgG serological assay for SARS-CoV-2
A serological test format that assesses antibodies to multiple viral proteins and includes methods to subtract cross-reactive antibodies to improve specificity, adapted from an assay architecture originally developed for herpesvirus serology.
HSV-based viral vector platform (adaptation project)
Platform work to convert an attenuated herpesvirus immunotherapeutic into a viral vector format for delivery of heterologous antigens for other vaccine applications.
Therapeutic live-attenuated HSV-2 vaccine candidate (lead)
A replication-competent, rationally attenuated herpesvirus vaccine candidate designed to modulate immune control of recurrent HSV infection via targeted mutations that reduce immune evasion; progressed through preclinical development with reported early clinical safety follow-up.
Prophylactic live-attenuated HSV vaccine candidates (HSV-1 and HSV-2)
Preclinical-stage replication-competent vaccine candidates intended for prevention of HSV-1 and HSV-2 infection developed using rational attenuation principles.
Multi-antigen IgG serological assay for SARS-CoV-2
A serological test format that assesses antibodies to multiple viral proteins and includes methods to subtract cross-reactive antibodies to improve specificity, adapted from an assay architecture originally developed for herpesvirus serology.
HSV-based viral vector platform (adaptation project)
Platform work to convert an attenuated herpesvirus immunotherapeutic into a viral vector format for delivery of heterologous antigens for other vaccine applications.
Expertise Areas
- Live-attenuated vaccine development
- Viral vector engineering
- Preclinical animal model evaluation
- Serological assay development
Key Technologies
- Live-attenuated viral vaccine platforms
- ICP0-targeted genetic attenuation
- HSV-based viral vectors
- Multi-antigen IgG serology
News & Updates
Agustin Fernandez III will present at the event, reviewing results from a five-year safety follow-up of the Phase 1 study of RVx201 for genital herpes caused by HSV-2.
The company announced a clinical trial to study patients with recurrent symptomatic HSV-2.
The company's experimental herpes vaccine has shown promising results in preclinical studies.
Further details on the preclinical promise of Rational Vaccines' herpes vaccine candidate.
Agustin Fernandez III will present at the event, reviewing results from a five-year safety follow-up of the Phase 1 study of RVx201 for genital herpes caused by HSV-2.
The company announced a clinical trial to study patients with recurrent symptomatic HSV-2.
The company's experimental herpes vaccine has shown promising results in preclinical studies.
Further details on the preclinical promise of Rational Vaccines' herpes vaccine candidate.